New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
08:37 EDTHTBXHeat Biologics to form CAB with immunotherapy, oncology experts
Heat Biologics announced the creation of a Clinical Advisory Board, or CAB, to actively design and guide its clinical trials and the appointment of four leading oncologists to serve on this board. Justin Stebbing, M.D., Ph.D. will serve as Chairman of the CAB and chief medical advisor to Heat. The CAB will work hand-in-hand with Heat's clinical team, led by Melissa Price, Ph.D., Vice President of Clinical and Regulatory Affairs. Dr. Stebbing will serve as lead advisor on the company's clinical trials.
News For HTBX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2015
13:47 EDTHTBXHeat Biologics focus on combo trial a positive, says Cantor
After Heat Biologics (HTBX) announced plans for a Phase 1b trial investigating the combination of its HS-110 vaccine and Bristol-Myers' (BMY) PD-1 inhibitor nivolumab in non-small cell lung cancer and said it is winding down its ongoing Phase 2 trial with HS-110 that does not include a checkpoint inhibitor combination, Cantor Fitzgerald analyst Mara Goldstein called the decision a positive. The new course preserves the current timeline and cash while making the clinical program more relevant to the evolving standard of care, according to Goldstein, who keeps a Buy rating and $18 price target on Heat Biologics shares.
07:16 EDTHTBXHeat Biologics to host conference call
Conference call to discuss clinical trial combining HS-110 and PD-1 checkpoint inhibitor in NSCLC will be held on September 1 at 8:30 am. Webcast Link
07:07 EDTHTBXHeat Biologics announces clinical trial combining HS-110, PD-1 in NSCLC
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use